Related Experiment Videos
Studies of von Willebrand factor in essential thrombocythemia patients treated with alpha-2b recombinant interferon
M G Mazzucconi1, A Ferrari, S Solinas
1Department of Human Biopathology, University La Sapienza, Rome, Italy.
Abstract:
The crucial role of the von Willebrand Factor (vWF) and its interaction with platelets in myeloproliferative disorders (MPD) have emerged in recent years. Recently, many authors have reported the therapeutical efficacy of interferon (IFN) in MPD with thrombocytosis in decreasing platelet number. The purpose of our report is to study the modifications of vWF in a series of 20 patients affected by essential thrombocythemia (ET) or MPD with thrombocytosis, treated with alpha 2b recombinant IFN (alpha 2b-rIFN). Patients were studied before treatment and after complete or partial response: vWF-related properties, bleeding time (BT) and ristocetin-induced platelet aggregation (RIPA) were evaluated. Before treatment, we found prolonged BT in 5 patients (25%), abnormal RIPA in 8 (40%), reduced factor VIII coagulant activity (VIII:C) in 2 (10%), reduced vWF-related antigen (vWF:Ag) in 5 (25%) and low vWF:ristocetin cofactor (vWF:Ricof) in 5 (25%). Twelve subjects were evaluated after hematologic remission: in all patients, BT, VIII:C, vWF:Ag and vWF:Ricof were within normal range or upper normal limits. RIPA was abnormal in 7 subjects. Multimer patterns of vWF were performed in 3 patients before and after treatment: 2 of them showed loss of high-molecular-weight multimers that seemed to recover at remission. IFN seems to induce improvement of platelet number and their functions in MPD with thrombocytosis.
Insights
Interferon therapy in myeloproliferative disorders with thrombocytosis improves platelet counts and function. von Willebrand Factor abnormalities often normalize with treatment, suggesting therapeutic benefits.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Myeloproliferative disorders (MPD) involve abnormal blood cell production.
- von Willebrand Factor (vWF) plays a key role in platelet function and MPD.
- Interferon (IFN) has shown efficacy in reducing platelet counts in MPD.
Purpose of the Study:
- To investigate the impact of alpha 2b recombinant interferon (alpha 2b-rIFN) on vWF properties in patients with essential thrombocythemia (ET) or MPD with thrombocytosis.
- To assess changes in bleeding time (BT), ristocetin-induced platelet aggregation (RIPA), and vWF parameters before and after IFN treatment.
Main Methods:
- Studied 20 patients with ET or MPD with thrombocytosis treated with alpha 2b-rIFN.
- Evaluated vWF-related properties, BT, and RIPA before treatment and after achieving hematologic remission.
- Assessed vWF antigen (vWF:Ag), vWF ristocetin cofactor (vWF:Ricof), factor VIII coagulant activity (VIII:C), and vWF multimer patterns.
Main Results:
- Before treatment, abnormalities included prolonged BT (25%), abnormal RIPA (40%), and reduced vWF:Ag/vWF:Ricof (25%).
- After remission, BT, VIII:C, vWF:Ag, and vWF:Ricof normalized or reached upper normal limits.
- RIPA remained abnormal in 70% of patients post-treatment; vWF multimer loss recovered in 2 out of 3 patients.
Conclusions:
- Alpha 2b-rIFN treatment improves platelet count and function in MPD with thrombocytosis.
- IFN therapy appears to normalize vWF parameters and potentially restore vWF multimer structure.
- Further research is warranted to fully elucidate the mechanisms of IFN's therapeutic effects in MPD.